Credit Suisse Maintains Outperform on Acuity Brands, Lowers Price Target to $200

Credit Suisse analyst John Walsh maintains Acuity Brands (NYSE:AYI) with a Outperform and lowers the price target from $211 to $200.

Credit Suisse analyst John Walsh maintains Acuity Brands (NYSE:AYI) with a Outperform and lowers the price target from $211 to $200.

Total
0
Shares
Related Posts
Read More

Reported Late Thursday March 2, Dispute Between Treace Medical and Fusion Orthopedics Resolved; Parties Entered Into An Agreement To Settle This Matter. While The Terms Of The Settlement Are Confidential, Fusion Orthopedics Is Pleased With The Outcome

Treace Medical Concepts, Inc. (NASDAQ:TMCI) ("Treace Medical") and Fusion Orthopedics, LLC ("Fusion Orthopedics") jointly announce that they have reached an amicable resolution of the litigation

TMCI